Oncology Institute Inc
Ownership
Ownership Structure
Who owns Oncology Institute Inc (TOI)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 86.7% of the shares are freely tradable; institutional investors hold 46.1%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BlackRock Inc | 4.42 | 4,415,867 | +13.1 | 03/31/2026 |
| Vanguard Capital Management, LLC | 3.48 | 3,476,781 | +0.0 | 03/31/2026 |
| Deerfield Management Co | 3.36 | 3,360,052 | +0.0 | 03/31/2026 |
| Kanen Wealth Management LLC | 2.78 | 2,777,858 | -6.7 | 03/31/2026 |
| JOSH ARNOLD INVESTMENT CONSULTANT, LLC | 2.46 | 2,464,359 | +0.2 | 03/31/2026 |
| Balyasny Asset Management LLC | 1.83 | 1,826,370 | -27.5 | 03/31/2026 |
| Geode Capital Management, LLC | 1.76 | 1,757,847 | +11.9 | 03/31/2026 |
| Wexford Capital LP | 1.71 | 1,711,323 | +11.6 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Morn Total Stk Mkt Idx Investor | 2.40 | 2,395,214 | -8.4 | 06/30/2026 |
| iShares Russell 2000 ETF | 1.99 | 1,992,247 | -0.1 | 07/30/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Chernett Jorey | 10% Owner | 10,660,858 | 66,097,320 $ | Aug 14, 2026 | direct |
| Hively Brad | Director | 411,976 | 2,554,251 $ | Aug 21, 2026 | direct |
| McGeorge Anne | Director | 332,535 | 2,061,717 $ | Jul 27, 2026 | direct |
| Johnson Karen Marie | Director | 319,410 | 1,980,342 $ | Jul 27, 2026 | direct |
| Pacala Mark L | Director | 286,881 | 1,778,662 $ | Jul 27, 2026 | direct |
| Podnos Yale | Chief Medical Officer | 259,527 | 1,609,067 $ | Jul 14, 2026 | direct |
| Kaushal Mohit | Director | 205,716 | 1,275,439 $ | Jul 27, 2026 | direct |
| Stolper Mark | Director | 56,957 | 353,133 $ | Jul 27, 2026 | direct |
| Tzoumakas Kimberly Jo | Director | 46,301 | 287,066 $ | Jul 27, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 21, 2026 | Hively Brad | Director | Sell | 298,853 | 6.51 | 1,946,310 |
| Aug 14, 2026 | Chernett Jorey | 10% Owner | Buy | 12,000 | 6.54 | 78,480 |
| Jul 27, 2026 | Kaushal Mohit | Director | Other | 33,133 | 0.00 | – |
| Jul 27, 2026 | McGeorge Anne | Director | Other | 41,165 | 0.00 | – |
| Jul 27, 2026 | Pacala Mark L | Director | Other | 30,120 | 0.00 | – |
| Jul 27, 2026 | Stolper Mark | Director | Other | 31,124 | 0.00 | – |
| Jul 27, 2026 | Tzoumakas Kimberly Jo | Director | Other | 29,116 | 0.00 | – |
| Jul 27, 2026 | Hively Brad | Director | Other | 27,108 | 0.00 | – |
| Jul 27, 2026 | Johnson Karen Marie | Director | Other | 31,124 | 0.00 | – |
| Jul 21, 2026 | Chernett Jorey | 10% Owner | Buy | 18,000 | 5.27 | 94,860 |
| Jul 14, 2026 | Podnos Yale | Chief Medical Officer | Sell | 5,478 | 6.35 | 34,785 |
| Jul 14, 2026 | Podnos Yale | Chief Medical Officer | Other | 5,478 | 2.00 | 10,956 |
| Jul 14, 2026 | Podnos Yale | Chief Medical Officer | Sell | 17,974 | 6.43 | 115,555 |
| Jul 14, 2026 | Podnos Yale | Chief Medical Officer | Other | 17,974 | 1.87 | 33,611 |
| Jul 10, 2026 | Chernett Jorey | 10% Owner | Buy | 15,000 | 5.85 | 87,750 |
| Jul 7, 2026 | Tzoumakas Kimberly Jo | Director | Other | 17,185 | 0.00 | – |
| Jul 7, 2026 | Stolper Mark | Director | Other | 25,833 | 0.00 | – |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: August 11, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.